Evidence map›Paper›PMID 38486719›Full record

ArticleThe World Allergy Organization journal2024

Diagnosis and treatment of

Kestutis Cerniauskas, Justina Rudyte, Kotryna Linauskiene, Anzelika Chomiciene, Linas Griguola, Laura Malinauskiene

Open access · goldAbstract read
In one paragraph

Article in The World Allergy Organization journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kestutis CerniauskasClinic of Chest Diseases, Immunology and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Justina RudytePulmonology and Allergology Center, VUH Santaros Klinikos, Vilnius, Lithuania.
Kotryna LinauskieneClinic of Chest Diseases, Immunology and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Anzelika ChomicieneClinic of Chest Diseases, Immunology and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Linas GriguolaPulmonology and Allergology Center, VUH Santaros Klinikos, Vilnius, Lithuania.
Laura MalinauskieneClinic of Chest Diseases, Immunology and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Vilnius University · LTVilnius University Hospital Santariskiu Klinikos · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Venom-specific immunotherapy (VIT) is a major treatment for patients allergic to Objective: We aimed to describe diagnostic and treatment experience data of VIT performed in a single center in Lithuania. Methods: In this retrospective study, we analyzed 9 years of clinical data (severity of the allergic reaction, recognition of the culprit insects, diagnostics, VIT protocol safety and efficacy, sting challenge outcomes) of patients treated with cluster VIT. Sting challenge helped to reveal the influence of venom preparation quality and to adjust the dosage of venom. Results: Data from 83 patients were analyzed. Double sensitization confirmed by component diagnosis was found in 39.4% (13/33), and double immunotherapy was initiated in 9.1% (n = 3/33). The cluster immunotherapy protocol was used in 81 patients. Systemic reactions occurred in 7.4% (n = 6/81) patients during the build-up phase. VIT failure was related to bee venom immunotherapy and systemic reactions during a build-up phase. The efficacy in the short term of our approach to cluster VIT was confirmed by the sting challenge in 97% (42/43). Nine patients (10.8%, n = 9/83) voluntarily stopped the treatment due to a lack of motivation. Conclusion: Our protocol regarding the investigation and treatment of patients allergic to

Indexed as

Cluster immunotherapyLithuaniaRetrospective studyVenom hypersensitivity

Identifiers

PMID38486719
PMCPMC10937955
OpenAlexW4392557847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.